Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Actos Now for Prevention of Diabetes (ACT NOW)

Trial Profile

Actos Now for Prevention of Diabetes (ACT NOW)

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Glucose intolerance; Type 2 diabetes mellitus
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms ACT-NOW
  • Most Recent Events

    • 16 Sep 2016 Results assessing the effect of pioglitazone on Fibroblast Growth Factor-21 (FGF-21), presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
    • 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association (n = 531).
    • 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top